GERN – Geron Corporation
Geron CorporationGERN
$0.982Name : Geron Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $632,513,728.00
EPSttm : -0.08
Geron Corporation
$0.982
3.75%$0.038
GERN — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
10.54
Margin Of Safety %
Put/Call OI Ratio
0.27
EPS Next Q Diff
EPS Last/This Y
0.11
EPS This/Next Y
0.11
Price
1
Target Price
3.5
Analyst Recom
1.4
Performance Q
-33.55
Upside
-340.2%
Beta
0.6
Ticker: GERN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | GERN | 1.205 | 0.28 | 10.79 | 73173 |
| 2026-10-14 | GERN | 1.185 | 0.28 | 0.05 | 73593 |
| 2026-10-15 | GERN | 1.225 | 0.28 | 0.77 | 73909 |
| 2026-10-16 | GERN | 1.175 | 0.28 | 0.02 | 74059 |
| 2026-10-19 | GERN | 1.195 | 0.29 | 0.06 | 70256 |
| 2026-10-20 | GERN | 1.23 | 0.29 | 0.10 | 70313 |
| 2026-10-21 | GERN | 1.15 | 0.29 | 0.04 | 70337 |
| 2026-10-22 | GERN | 1.125 | 0.28 | 0.11 | 71121 |
| 2026-10-23 | GERN | 1.115 | 0.28 | 0.26 | 71309 |
| 2026-10-26 | GERN | 1.15 | 0.28 | 0.17 | 71774 |
| 2026-10-27 | GERN | 1.14 | 0.28 | 0.19 | 71982 |
| 2026-10-28 | GERN | 0.9659 | 0.28 | 0.53 | 72114 |
| 2026-10-29 | GERN | 0.9415 | 0.29 | 0.60 | 74184 |
| 2026-10-30 | GERN | 0.8931 | 0.29 | 0.16 | 74330 |
| 2026-11-02 | GERN | 0.9295 | 0.27 | 0.02 | 75086 |
| 2026-11-03 | GERN | 0.9367 | 0.27 | 0.09 | 75738 |
| 2026-11-04 | GERN | 1.075 | 0.27 | 0.05 | 76021 |
| 2026-11-05 | GERN | 0.9501 | 0.27 | 0.00 | 76271 |
| 2026-11-06 | GERN | 0.9878 | 0.27 | 0.06 | 76308 |
| 2026-11-09 | GERN | 0.9905 | 0.27 | 0.29 | 76246 |
| 2026-11-10 | GERN | 0.9719 | 0.27 | 0.00 | 76285 |
| 2026-11-11 | GERN | 1.005 | 0.27 | 0.01 | 76119 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | GERN | 1.21 | 66.7 | 63.9 | -0.02 |
| 2026-10-14 | GERN | 1.19 | 66.7 | 64.1 | -0.02 |
| 2026-10-15 | GERN | 1.23 | 66.7 | 65.2 | -0.02 |
| 2026-10-16 | GERN | 1.17 | 66.7 | 62.9 | -0.02 |
| 2026-10-19 | GERN | 1.20 | 66.7 | 65.0 | -0.02 |
| 2026-10-20 | GERN | 1.20 | 66.7 | 65.0 | -0.02 |
| 2026-10-21 | GERN | 1.24 | 66.7 | 65.8 | -0.02 |
| 2026-10-22 | GERN | 1.12 | 66.7 | 63.8 | -0.02 |
| 2026-10-23 | GERN | 1.12 | 66.7 | 63.8 | -0.02 |
| 2026-10-26 | GERN | 1.15 | 66.7 | 65.8 | -0.02 |
| 2026-10-27 | GERN | 1.14 | 66.7 | 64.6 | -0.02 |
| 2026-10-28 | GERN | 0.97 | 66.7 | 58.9 | -0.02 |
| 2026-10-29 | GERN | 0.95 | 66.7 | 63.7 | -0.02 |
| 2026-10-30 | GERN | 0.89 | 66.7 | 62.4 | -0.02 |
| 2026-11-02 | GERN | 0.93 | - | 66.0 | -0.04 |
| 2026-11-03 | GERN | 0.94 | - | 66.3 | -0.04 |
| 2026-11-04 | GERN | 1.08 | - | 70.1 | -0.04 |
| 2026-11-05 | GERN | 0.95 | - | 43.0 | -0.04 |
| 2026-11-06 | GERN | 0.99 | - | 47.6 | -0.04 |
| 2026-11-09 | GERN | 0.99 | - | 46.2 | -0.04 |
| 2026-11-10 | GERN | 0.97 | - | 45.3 | -0.04 |
| 2026-11-11 | GERN | 1.00 | - | 47.3 | -0.02 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | GERN | 0.00 | -0.14 | 11.67 |
| 2026-10-14 | GERN | 0.00 | -0.14 | 11.67 |
| 2026-10-15 | GERN | 0.00 | -0.14 | 11.67 |
| 2026-10-16 | GERN | 0.00 | -0.14 | 11.67 |
| 2026-10-19 | GERN | 0.00 | -0.17 | 11.67 |
| 2026-10-20 | GERN | 0.00 | -0.17 | 11.67 |
| 2026-10-21 | GERN | 0.00 | -0.17 | 11.67 |
| 2026-10-22 | GERN | 0.00 | -0.17 | 11.67 |
| 2026-10-23 | GERN | 0.00 | -0.17 | 11.67 |
| 2026-10-26 | GERN | 0.00 | -0.77 | 11.67 |
| 2026-10-27 | GERN | 0.00 | -0.77 | 11.78 |
| 2026-10-28 | GERN | 0.00 | -0.77 | 11.78 |
| 2026-10-29 | GERN | 0.00 | -0.77 | 11.78 |
| 2026-10-30 | GERN | 0.00 | -0.77 | 11.78 |
| 2026-11-02 | GERN | 0.00 | -0.92 | 11.78 |
| 2026-11-03 | GERN | 0.00 | -0.92 | 11.78 |
| 2026-11-05 | GERN | 0.00 | -0.92 | 11.78 |
| 2026-11-06 | GERN | 0.00 | -0.92 | 11.78 |
| 2026-11-09 | GERN | 0.00 | -1.60 | 11.75 |
| 2026-11-10 | GERN | 0.00 | -1.60 | 11.75 |
| 2026-11-11 | GERN | 0.00 | -1.60 | 10.54 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
0.01
Avg. EPS Est. Next Quarter
0.01
Insider Transactions
Institutional Transactions
-1.6
Beta
0.6
Average Sales Estimate Current Quarter
65
Average Sales Estimate Next Quarter
75
Fair Value
Quality Score
53
Growth Score
47
Sentiment Score
84
Actual DrawDown %
81.3
Max Drawdown 5-Year %
-82.4
Target Price
3.5
P/E
Forward P/E
14.17
PEG
P/S
3.02
P/B
2.9
P/Free Cash Flow
EPS
-0.07
Average EPS Est. Cur. Y
-0.02
EPS Next Y. (Est.)
0.09
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-23.04
Relative Volume
0.54
Return on Equity vs Sector %
-47.5
Return on Equity vs Industry %
-27.9
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
47.3
◆
GERN
Healthcare
$1.02
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
44.3
Range 1M
38.8%
Sup Dist
8.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
78.5%
EPS NY
357.1%
52W%
13.3%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+218.6% upside
Upside
+218.6%
Quality
53
GERN — P/E HistoricalBiotechnology
Geron CorporationSector: Healthcare
Industry: Biotechnology
Employees: 258
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
GERN
Latest News
—
Caricamento notizie per GERN…
stock quote shares GERN – Geron Corporation Stock Price stock today
news today GERN – Geron Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch GERN – Geron Corporation yahoo finance google finance
stock history GERN – Geron Corporation invest stock market
stock prices GERN premarket after hours
ticker GERN fair value insiders trading